Domov › Burkittov limfom › Colorado
Klinične študije za Burkittov limfom v Colorado
13 študij za Burkittov limfom išče udeležence na lokacijah v Colorado.
Mesta v Colorado
Uradno besedilo študije (angleško)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Colorado, Aurora
Vključevanje udeležencevFaza 2
366 Days – 46 Years · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06124157Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital Colorado, Aurora
Vključevanje udeležencevOpazovalna študija
Starost 0–38 · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06131801Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Hospital Colorado, Aurora
Vključevanje udeležencevFaza 2
365 Days · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- CBCI, Colorado Blood Cancer Institute, Denver
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT07648264Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora
Vključevanje udeležencevFaza 1/2
6 Months – 25 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT06395103UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
- Children's Hospital Colorado, Aurora
Vključevanje udeležencevFaza 1/2
31 Days – 30 Years · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT04544592A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Colorado, Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
Vključevanje udeležencevFaza 2
Starost 1–30 · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospital Colorado, Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
Vključevanje udeležencevFaza 3
365 Days – 25 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Colorado Children's Hospital, Denver
Vključevanje udeležencevFaza 2
Starost 7–25 · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Colorado Blood Cancer Institute, Denver
Vključevanje udeležencevFaza 1/2
Starost 13–90 · Vsi spoli · Posodobljeno 6. avg. 2026 · NCT06533579CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
- Children's Hospital Colorado, Aurora
Vključevanje udeležencevFaza 1
3 Months – 30 Years · Vsi spoli · Posodobljeno 28. nov. 2025 · NCT06559189Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- University of Colorado - Aurora Cancer Center, Aurora
- Sarah Cannon - Colorado Blood Cancer Institute, Denver
Vključevanje udeležencevFaza 1/2
Starost 15–50 · Vsi spoli · Posodobljeno 9. sep. 2025 · NCT04150497The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Children's Hospital Colorado, Aurora
Vključevanje udeležencevFaza 2
Starost 1–25 · Vsi spoli · Posodobljeno 4. maj 2025 · NCT03509961Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.